contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


transactions-in-zealand-pharma-shares-andor-related-securities-by-persons-discharging-managerial-responsibilities-andor-their-closely-associated-persons-47

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Zealand Pharma

Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons...

Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit <a href="https://www.globenewswire.com/Tracker?data=SNxJ7v9rtsrkeQuaIVsxsVfufomeeieZg7Oq991nIaJhw5omZwuFlMDmlJHtpn_12If_F2hh8-LkBEjVjkeIhiaveUPTBawFVBHE0o65SaU=">www.zealandpharma.com</a>. Contacts Adam Lange (Investors) Vice President, Investor Relations Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=-2Puei6Eybd4iTz6rv2ncKTEOSkeaAZwHY77uXxIOG50fWCzV-x9DQGzV9CMh__-cn7otRJEg_hcbfpoKNmlsaGwyzuhWbFpFEZw7LSkI7Lx0BWj8EJGebD3IfedRSc_">alange@zealandpharma.com</a> Neshat Ahmadi (Investors) Investor Relations Manager Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=JnL585Fewc-Jg7xFfFK678doLKi6x1z4uqGJemQkL8XP1sfgvh5omp3CxR4TRcgRDwI3TlFsbs6IIba90nHuPYNzhDof73lBTOuOPAgnS3OCOEX5eE1JxA7beEQE21Da">neahmadi@zealandpharma.com</a> Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations &amp; Corporate Communications Zealand Pharma Email:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=fA1mUMncoi2UbeUqVDYLQJymrcYApSFEBD-_pRzbpIZ6N2jz7xUPu3nrn5F3TofetLLEpJv799HXyLgSKL0GHKD-YrJifdpp1PlX6EuSvLASWsAj7v3Y97P5JoxoN-OycaiOL0DBV71snuhzI_C3gwqE8iYpV-0OUw94tuwYleBcSoRDxPrNgbsY-fzC1WNRzjnz_Y_RRTKkNFDm2_qQCV4OoedP7P_M1yRtxusCryl991uh-ne0CHX8cCI3CBeB63KqA9eJlKttYutdnRYhOEX-nPjxpCBGngVh007QhJ8BdpvuZF-E3yQ6jsTI-hOH9a0miV6BIfx5kXyIXBlpy0gdG09I1YbX-f2l52XgSwJ4TvsQZd2Jy5j61qQ5X-AfHXQTmIp-gvhOX2lwZuUNsum7lHDmunukIsU3Lr3nm4Hzz-Dh3-MXEIandgHqxvrL023D_4OX25mNmeNCcbvDz3tBIFpBK85AqWkKDhzE0Z_e5R27dQCYpNf5LZcVH4qoKwzB4lujLViBjFuYfdoai_HyNbEFvg_yIm1dXc-ykuuBsdM0pHkqgFRx8V1wS0nU">akrassowska@zealandpharma.com</a> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/373c08ac-91ad-40a8-b61d-d0aefd6ef59d">27.05.2025 - PDMR notification Adam Steensberg</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA5OTIyMCM0MDIxNDg4ODMjMjAwMTcwMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ZDJmNTRlNWQtOTQ4Ny00NDg1LThhZjUtODQ2N2M4OWMzMzBmLTEwMTMyNzQtMjAyNS0wNS0yNy1lbg==/tiny/Zealand-Pharma.png" alt="">

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons